Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn

ObjectiveWe previously reported improved oxygenation, but no change, in rates of extracorporeal membrane oxygenation (ECMO) use or death among infants with persistent pulmonary hypertension of the newborn who received inhaled nitric oxide (NO) with conventional ventilation, irrespective of lung disease. The goal of our study was to determine whether treatment with inhaled NO improves oxygenation and clinical outcomes in infants with persistent pulmonary hypertension of the newborn and associated lung disease who are ventilated with high-frequency oscillatory ventilation (HFOV). DesignSingle-center, prospective, randomized, controlled trial. SettingNewborn intensive care unit of a tertiary care teaching hospital. PatientsWe studied infants with a gestational age of ≥34 wks who were receiving mechanical ventilatory support and had echocardiographic and clinical evidence of pulmonary hypertension and hypoxemia (Pao2 ≤100 mm Hg on Fio2 = 1.0), despite optimal medical management. Infants with congenital heart disease, diaphragmatic hernia, or other major anomalies were excluded. InterventionsThe treatment group received inhaled NO, whereas the control group did not. Adjunct therapies and ECMO criteria were the same in the two groups of patients. Investigators and clinicians were not masked as to treatment assignment, and no crossover of patients was permitted. Measurements and Main ResultsPrimary outcome variables were mortality and use of ECMO. Secondary outcomes included change in oxygenation and duration of mechanical ventilatory support and supplemental oxygen therapy. Forty-two patients were enrolled. Baseline oxygenation and clinical characteristics were similar in the two groups of patients. Infants in the inhaled NO group (n = 21) had improved measures of oxygenation at 15 mins and 1 hr after enrollment compared with infants in the control group (n = 20). Fewer infants in the inhaled NO group compared with the control group were treated with ECMO (14% vs. 55%, respectively;p = .007). Mortality did not differ with treatment assignment. ConclusionsAmong infants ventilated by HFOV, those receiving inhaled NO had a reduced need for ECMO. We speculate that HFOV enhances the effectiveness of inhaled NO treatment in infants with persistent pulmonary hypertension of the newborn and associated lung disease.

[1]  J. Kattwinkel,et al.  Inhaled Nitric Oxide for the Early Treatment of Persistent Pulmonary Hypertension of the Term Newborn: A Randomized, Double-Masked, Placebo-Controlled, Dose-Response, Multicenter Study , 1998, Pediatrics.

[2]  A. Stark,et al.  Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. , 1997, Pediatrics.

[3]  G. Redding,et al.  Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn , 1997 .

[4]  A. Stark,et al.  Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5'-monophosphate plasma concentrations in newborn infants with persistent pulmonary hypertension. , 1997, The Journal of pediatrics.

[5]  Jesse D. Roberts,et al.  Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn , 1997 .

[6]  Cook,et al.  Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. , 1997, The New England journal of medicine.

[7]  D. Shannon,et al.  Whole Body Arginine Metabolism and Nitric Oxide Synthesis in Newborns with Persistent Pulmonary Hypertension , 1995, Pediatric Research.

[8]  S. Abman,et al.  Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. , 1994, The Journal of pediatrics.

[9]  P. Hickey,et al.  Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension , 1994, Critical care medicine.

[10]  J. Arnold,et al.  Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. , 1994, The Annals of thoracic surgery.

[11]  R. Trifiletti,et al.  Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. , 1994, Biology of the neonate.

[12]  D. Wessel,et al.  Use of Inhaled Nitric Oxide and Acetlcholine in the Evaluation of Pulmonary Hypertension and Endothelial Function After Cardiopulmonary Bypass , 1993, Circulation.

[13]  E. Shaffer,et al.  Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. , 1993, The Journal of pediatrics.

[14]  R. Rossaint,et al.  Inhaled nitric oxide for the adult respiratory distress syndrome. , 1993, New England Journal of Medicine.

[15]  E. Shaffer,et al.  Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn , 1992, The Lancet.

[16]  Jesse D. Roberts,et al.  Inhaled nitric oxide in persistent pulmonary hypertension of the newborn , 1992, The Lancet.

[17]  D. Katayose,et al.  Modulatory role of EDRF in hypoxic contraction of isolated porcine pulmonary arteries. , 1992, The American journal of physiology.

[18]  T. Higenbottam,et al.  Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension , 1991, The Lancet.

[19]  J. Wain,et al.  Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator Reversing Hypoxic Pulmonary Vasoconstriction , 1991, Circulation.

[20]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[21]  L. Ignarro,et al.  Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. , 1986, The Journal of pharmacology and experimental therapeutics.